IFNB1 and myeloid sarcoma: However, despite the clinical efficacy of IFN-β, approximately 25–40% of RRMS patients respond poorly to this treatment [1], and it consistently worsens disease in patients with neuromyelitis optica (NMO), a neuroinflammatory disease often misdiagnosed as MS [2,3].